Gilad Oren's Insider Trades & SAST Disclosures
Gilad Oren's most recent trade in Aprea Therapeutics Inc was a trade of 500 Common Stock done at an average price of $3.9 . Disclosure was reported to the exchange on Oct. 23, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gilad Oren.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aprea Therapeutics Inc | Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 3.92 per share. | 23 Oct 2024 | 500 | 333,395 (1%) | 0% | 3.9 | 1,958 | Common Stock |
| Aprea Therapeutics Inc | Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 15 Oct 2024 | 250 | 332,895 (1%) | 0% | 2.9 | 725 | Common Stock |
| Aprea Therapeutics Inc | Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.59 per share. | 10 Oct 2024 | 1,000 | 332,645 (1%) | 0% | 2.6 | 2,590 | Common Stock |
| Aprea Therapeutics Inc | Oren Gilad | Director, President/CEO | Purchase of securities on an exchange or from another person at price $ 2.54 per share. | 10 Oct 2024 | 150 | 331,645 (1%) | 0% | 2.5 | 381 | Common Stock |
| Aprea Therapeutics Inc | Gilad Oren | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 26,900 | 26,900 | - | - | Stock Options (Right to Buy) | |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 6,725 | 331,495 (1%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 13 Mar 2024 | 2,000 | 324,770 (1%) | 0% | 7.3 | 14,580 | Common Stock |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 1,000 | 1,000 | - | - | Tranche A Warrant | |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 13 Mar 2024 | 1,000 | 1,000 | - | - | Tranche B Warrant | |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | 23 Aug 2022 | 6,045,100 | 6,375,414 (30%) | 28% | 0 | Common Stock | ||
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | 23 Aug 2022 | 604,510 | 0 | - | - | Series A Non-Voting Convertible Preferred Stock | ||
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 16,000 | 16,000 | - | - | Stock Options (Right to Buy) | |
| Aprea Therapeutics Inc | Oren Gilad | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 4,000 | 322,770 (1%) | 0% | 0 | Common Stock | |
| Aprea Therapeutics Inc | Oren Gilad | President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 148,700 | 148,700 | - | - | Stock Option (right to Buy) | |
| Aprea Therapeutics Inc | Oren Gilad | President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 101,300 | 330,314 (1%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges